| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
Molecular Diagnostic Laboratory,1 Departments of Clinical Biochemistry,2 Urology, and 3 Oncology, Aarhus University Hospital; and 4 Bioinformatics Research Center, Aarhus University, Aarhus, Denmark
Requests for reprints: Torben F. Ørntoft, Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK-8200 Aarhus, Denmark. Phone: 45-894-95100; Fax: 45-894-96018; E-mail: orntoft{at}kba.sks.au.dk.
Bladder cancer is a common disease characterized by multiple recurrences and an invasive disease course in more than 10% of patients. It is of monoclonal or oligoclonal origin and genomic instability has been shown at certain loci. We used a 10,000 single nucleotide polymorphism (SNP) array with an average of 2,700 heterozygous SNPs to detect allelic imbalances (AI) in 37 microdissected bladder tumors from 17 patients. Eight tumors represented upstaging from Ta to T1, eight from T1 to T2+, and one from Ta to T2+. The AI was strongly stage-dependent as four chromosomal arms showed AI in > 50% of Ta samples, eight in T1, and twenty-two in T2+ samples. The tumors showed stage-dependent clonality as 61.3% of AIs were reconfirmed in later T1 tumors and 84.4% in muscle-invasive tumors. Novel unstable chromosomal areas were identified at chromosomes 6q, 10p, 16q, 20p, 20q, and 22q. The tumors separated into two distinct groups, highly stable tumors (all Ta tumors) and unstable tumors (2/3 muscle-invasive). All 11 unstable tumors had lost chromosome 17p areas and 90% chromosome 8 areas affecting Netrin-1/UNC5D/MAP2K4 genes as well as others. AI was present at the TP53 locus in 10 out of 11 unstable tumors, whereas 6 had homozygous TP53 mutations. Tumor distribution pattern reflected AI as seven out of eight patients with additional upper urinary tract tumors had genomic stable bladder tumors (P < 0.05). These data show the power of high-resolution SNP arrays for defining clinically relevant AIs.
Key Words: bladder cancer single nucleotide polymorphism loss of heterozygosity allelic imbalance TP53 mutations
This article has been cited by other articles:
![]() |
A. Veerakumarasivam, H. E. Scott, S.-F. Chin, A. Warren, M. J. Wallard, D. Grimmer, K. Ichimura, C. Caldas, V. P. Collins, D. E. Neal, et al. High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53 Clin. Cancer Res., May 1, 2008; 14(9): 2527 - 2534. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Rauch, X. Zhong, X. Wu, M. Wang, K. H. Kernstine, Z. Wang, A. D. Riggs, and G. P. Pfeifer High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer PNAS, January 8, 2008; 105(1): 252 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Andersen, C. Wiuf, M. Kruhoffer, M. Korsgaard, S. Laurberg, and T. F. Orntoft Frequent occurrence of uniparental disomy in colorectal cancer Carcinogenesis, January 1, 2007; 28(1): 38 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Peiffer, J. M. Le, F. J. Steemers, W. Chang, T. Jenniges, F. Garcia, K. Haden, J. Li, C. A. Shaw, J. Belmont, et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping Genome Res., September 1, 2006; 16(9): 1136 - 1148. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aaboe, K. Birkenkamp-Demtroder, C. Wiuf, F. B. Sorensen, T. Thykjaer, G. Sauter, K. M.-E. Jensen, L. Dyrskjot, and T. Orntoft SOX4 Expression in Bladder Carcinoma: Clinical Aspects and In vitro Functional Characterization. Cancer Res., April 1, 2006; 66(7): 3434 - 3442. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Lips, J. W. F. Dierssen, R. van Eijk, J. Oosting, P. H.C. Eilers, R. A.E.M. Tollenaar, E. J. de Graaf, R. van't Slot, C. Wijmenga, H. Morreau, et al. Reliable High-Throughput Genotyping and Loss-of-Heterozygosity Detection in Formalin-Fixed, Paraffin-Embedded Tumors Using Single Nucleotide Polymorphism Arrays Cancer Res., November 15, 2005; 65(22): 10188 - 10191. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zieger, L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L. Andersen, K. M.-E. Jensen, and T. F. Orntoft Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors Clin. Cancer Res., November 1, 2005; 11(21): 7709 - 7719. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Di, H. Matsuzaki, T. A. Webster, E. Hubbell, G. Liu, S. Dong, D. Bartell, J. Huang, R. Chiles, G. Yang, et al. Dynamic model based algorithms for screening and genotyping over 100K SNPs on oligonucleotide microarrays Bioinformatics, May 1, 2005; 21(9): 1958 - 1963. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |